Martin Ebinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4421069/publications.pdf Version: 2024-02-01

		101543	30087
127	11,522	36	103
papers	citations	h-index	g-index
121	121	121	15702
151	151	151	13723
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
2	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
3	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
4	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
5	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
6	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
7	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
8	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	27.8	520
9	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
10	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncology, The, 2020, 21, 121-133.	10.7	204
11	Simultaneous Whole-Body PET/MR Imaging in Comparison to PET/CT in Pediatric Oncology: Initial Results. Radiology, 2014, 273, 220-231.	7.3	191
12	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
13	Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplantation, 2015, 50, S6-S10.	2.4	145
14	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget, 2016, 7, 76902-76919.	1.8	131
15	Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica, 2014, 99, 1212-1219.	3.5	125
16	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
17	Transplantation of <scp>CD</scp> 3/ <scp>CD</scp> 19 depleted allografts from haploidentical family donors in paediatric leukaemia. British Journal of Haematology, 2014, 165, 688-698.	2.5	109
18	Haploidentical Stem Cell Transplantation in Patients with Pediatric Solid Tumors: Preliminary Results of a Pilot Study and Analysis of Graft versus Tumor Effects. Klinische Padiatrie, 2006, 218, 321-326.	0.6	79

#	Article	IF	CITATIONS
19	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. PLoS ONE, 2015, 10, e0120925.	2.5	78
20	Childhood supratentorial ependymomas with <i>YAP1â€MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
21	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
22	Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplantation, 2011, 46, 1045-1052.	2.4	70
23	Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. Journal of General Virology, 2006, 87, 2941-2949.	2.9	60
24	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60
25	Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging. Investigative Radiology, 2016, 51, 7-14.	6.2	58
26	POST-TEXT III and IV Hepatoblastoma. Annals of Surgery, 2017, 266, 318-323.	4.2	57
27	Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. Biology of Blood and Marrow Transplantation, 2018, 24, 1005-1012.	2.0	55
28	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia, 2020, 34, 151-166.	7.2	53
29	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. European Journal of Cancer, 2019, 114, 27-35.	2.8	51
30	High frequency of H3 K27M mutations in adult midline gliomas. Journal of Cancer Research and Clinical Oncology, 2019, 145, 839-850.	2.5	50
31	Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. Haematologica, 2017, 102, e52-e56.	3.5	49
32	Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. Journal of Cancer Research and Clinical Oncology, 2016, 142, 89-100.	2.5	46
33	Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathology and Oncology Research, 2004, 10, 17-21.	1.9	45
34	High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia. Pediatric Hematology and Oncology, 2011, 28, 91-99.	0.8	43
35	EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia, 2013, 27, 56-65.	7.2	41
36	Beneficial impact of high-field intraoperative magnetic resonance imaging on the efficacy of pediatric low-grade glioma surgery. Neurosurgical Focus, 2016, 40, E13.	2.3	39

#	Article	IF	CITATIONS
37	CD34 ⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. British Journal of Haematology, 2018, 180, 90-99.	2.5	39
38	Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplantation, 2007, 39, 767-773.	2.4	38
39	Blinatumomab in pediatric patients with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia. European Journal of Haematology, 2021, 106, 473-483.	2.2	38
40	Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2017, 37, 770-780.	3.8	37
41	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 170-181.	3.5	37
42	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	7.7	37
43	Highâ€dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival—The Gesellschaft für Pâiatrische Onkologie und Hänatologie (GPOH) experience. Pediatric Blood and Cancer, 2018, 65, e26746.	1.5	35
44	Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. Blood, 2009, 113, 4049-4051.	1.4	34
45	Demographics and diagnosis of pyridoxine-dependent seizures. Journal of Pediatrics, 1999, 134, 795.	1.8	33
46	Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcl̂³null mice reflects individual leukemogenecity and highly correlates with clinical outcome. International Journal of Cancer, 2013, 133, 1547-1556.	5.1	33
47	Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1189-1200.	2.9	33
48	Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Haematologica, 2013, 98, 1948-1955.	3.5	29
49	Treatment of graft failure with <scp>TNI</scp> â€based reconditioning and haploidentical stem cells in paediatric patients. British Journal of Haematology, 2016, 175, 115-122.	2.5	29
50	Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A) Tj ETQq0 0 C) rgBT /Ονα 2.4	erlggk 10 Tf 5
51	High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leukemia Research, 2010, 34, 1139-1142.	0.8	25
52	Neurotoxic side effects in children with refractory or relapsed Tâ€cell malignancies treated with nelarabine based therapy. British Journal of Haematology, 2017, 179, 272-283.	2.5	25
53	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	12.8	24

⁵⁴Minimally Invasive Surgery for Pediatric Tumors ââ,¬â€œ Current State of the Art. Frontiers in Pediatrics,
2014, 2, 48.1.923

#	Article	IF	CITATIONS
55	Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Practice and Research in Clinical Haematology, 2011, 24, 403-411.	1.7	22
56	Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes. Pediatric Blood and Cancer, 2016, 63, 611-617.	1.5	22
57	Both mature KIR+ and immature KIRâ^' NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. Blood, 2014, 124, 3914-3923.	1.4	20
58	LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis. Blood, 2019, 134, 1159-1175.	1.4	20
59	Sickle cell disease in Germany: Results from a national registry. Pediatric Blood and Cancer, 2020, 67, e28130.	1.5	20
60	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. Molecular Therapy, 2016, 24, 1634-1643.	8.2	18
61	Computer-assisted surgery planning in children with complex liver tumors identifies variability of the classical Couinaud classification. Journal of Pediatric Surgery, 2016, 51, 1801-1806.	1.6	16
62	Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae. Annals of Hematology, 2019, 98, 1617-1626.	1.8	16
63	Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients. Bone Marrow Transplantation, 2015, 50, S72-S76.	2.4	15
64	The extraordinary challenge of treating patients with congenital rhabdoid tumors—a collaborative European effort. Pediatric Blood and Cancer, 2018, 65, e26999.	1.5	15
65	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. Cancer Genetics, 2014, 207, 434-436.	0.4	14
66	Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab. OncoTargets and Therapy, 2017, Volume 10, 3567-3578.	2.0	14
67	Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Medical Mycology, 2016, 55, myw091.	0.7	13
68	Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E88-E94.	3.5	12
69	Isolation of Capnocytophaga granulosa from an Abscess in an Immunocompetent Adolescent. Clinical Infectious Diseases, 2000, 30, 606-607.	5.8	12
70	Perioperative epidural analgesia in children undergoing major abdominal tumor surgery — a single center experience. Journal of Pediatric Surgery, 2014, 49, 551-555.	1.6	12
71	Feasibility and possible value of quantitative semi-automated diffusion weighted imaging volumetry of neuroblastic tumors. Cancer Imaging, 2020, 20, 89.	2.8	12
72	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11

#	Article	IF	CITATIONS
73	Simplified detection of microsatellite instability in colorectal cancer without the need for corresponding germline DNA analysis. Journal of Clinical Pathology, 2006, 59, 1114-1115.	2.0	10
74	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma Journal of Clinical Oncology, 2018, 36, 10525-10525.	1.6	10
75	Legal uncertainties in international high seas fisheries management. Fisheries Research, 1998, 37, 225-237.	1.7	9
76	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatric Blood and Cancer, 2021, 68, e28963.	1.5	9
77	Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy. Pediatric Hematology and Oncology, 2011, 28, 334-337.	0.8	8
78	Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature. Medical Mycology Case Reports, 2021, 32, 4-9.	1.3	8
79	Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica, 2021, 106, 3232-3235.	3.5	8
80	NO ABERRANT METHYLATION OF NEUROFIBROMATOSIS 1 GENE (NF1) PROMOTER IN PILOCYTIC ASTROCYTOMA IN CHILDHOOD. Pediatric Hematology and Oncology, 2005, 22, 83-87.	0.8	7
81	Children with Relapsed or Refractory Nephroblastoma: Favorable Long-term Survival after High-dose Chemotherapy and Autologous Stem Cell Transplantation. Klinische Padiatrie, 2014, 226, 351-356.	0.6	7
82	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. Cancers, 2021, 13, 1876.	3.7	7
83	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatric Blood and Cancer, 2021, 68, e29267.	1.5	7
84	Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 857-866.	2.5	7
85	Standard mono- and dinucleotide repeats do not appear to be sensitive markers of microsatellite instability in the Ewing family of tumors. Cancer Genetics and Cytogenetics, 2005, 157, 189-190.	1.0	6
86	Diagnostic value of whole-body MRI in Opsoclonus-myoclonus syndrome: a clinical case series (3 case) Tj ETQq0	0 0 rgBT /	Overlock 10 1
87	Immunosuppressive Total Nodal Irradiation–Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation. International Journal of Radiation Oncology Biology Physics, 2019, 104, 137-143.	0.8	6
88	Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children. Transplantation and Cellular Therapy, 2021, 27, 71.e1-71.e12.	1.2	6
89	Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma Journal of Clinical Oncology, 2015, 33, 10056-10056.	1.6	6
90	<p>Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies</p> . Drug Design, Development and Therapy, 2019, Volume 13, 3439-3451.	4.3	5

6

#	Article	IF	CITATIONS
91	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. Bone Marrow Transplantation, 2019, 54, 689-693.	2.4	5
92	Arsenic trioxide in pediatric cancer – a case series and review of literature. Pediatric Hematology and Oncology, 2021, 38, 471-485.	0.8	5
93	Expression of GAS7 in childhood CNS tumors. Pediatric Blood and Cancer, 2006, 46, 325-328.	1.5	4
94	<i>PAX6</i> is frequently expressed in ependymal tumours and associated with prognostic relevant subgroups. Journal of Clinical Pathology, 2022, 75, 759-765.	2.0	4
95	Abstract A013: Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma. Cancer Immunology Research, 2019, 7, A013-A013.	3.4	4
96	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. Bone Marrow Transplantation, 2019, 54, 53-62.	2.4	3
97	Flow Cytometry for Detection and Quantification of Micrometastases in Sentinel Lymph Nodes from Patients with Primary Melanoma. Journal of Surgical Research, 2021, 257, 477-485.	1.6	3
98	Comparing efficacy and side effects of two systemic chemotherapy regimens for eyeâ€preserving therapy in children with retinoblastoma. Pediatric Blood and Cancer, 2022, 69, e29362.	1.5	3
99	The genomic landscape of pediatric renal cell carcinomas. IScience, 2022, 25, 104167.	4.1	3
100	Incidences and characteristics of primary lung malignancies in childhood in Germany: An analysis of populationâ€based data from German cancer registries. Pediatric Blood and Cancer, 2022, 69, e29744.	1.5	3
101	Therapy Response Correlates with ALDH Activity in ALDH Low-Positive Childhood Acute Lymphoblastic Leukemias. Pediatric Hematology and Oncology, 2014, 31, 303-310.	0.8	2
102	Unilateral Hearing Loss Due to Cochlear Nerve Involvement as Isolated Symptom of a Primary Medulloblastoma. Neuropediatrics, 2020, 51, 170-172.	0.6	1
103	Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients. Cancer Immunology Research, 2019, 7, B124-B124.	3.4	1
104	Transplantation Of TcRαβ/CD19 Depleted Stem Cells From Haploidentical Donors In Children: Current Results. Blood, 2013, 122, 692-692.	1.4	1
105	Leukemia Related Co-Stimulation / Co-Inhibition Predict T-Cell Attack of Acute Lymphoblastic Leukemia Mediated By Blinatumomab. Blood, 2015, 126, 3764-3764.	1.4	1
106	Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial. Blood, 2019, 134, 2804-2804.	1.4	1
107	Introducing isotonic fluids into pediatric oncology. Pediatric Hematology and Oncology, 2021, , 1-8.	0.8	1
108	Arsenic Trioxide Inhibits Growth of Rhabdoid Cell Line KD. Cancer Genetics, 2014, 207, 455-456.	0.4	0

ARTICLE IF CITATIONS Transplantation of Haploidentical CD3/CD19 Depleted Stem Cells in Children: Final Results of a Multicenter Phase I/II Study. Biology of Blood and Marrow Transplantation, 2016, 22, S62. IMMU-28. DECIPHERING THE AT/RT LIGANDOME. Neuro-Oncology, 2018, 20, i104-i104. 110 1.2 0 ATRT-16. CONGENITAL RHABDOID TUMORS AS A MAJOR CLINICAL CHALLENGE - A COLLABORATIVE EUROPEAN 111 1.2 EFFORT. Neuro-Oncology, 2018, 20, i30-i31. ATRT-06. CLINICAL AND MOLECULAR RISK FACTORS IN CHILDREN WITH ATYPICAL TERATOID/RHABDOID 112 1.2 0 TUMOUR (AT/RT) - EVIDENCE FROM THE EU-RHAB REGISTRY. Neuro-Oncology, 2018, 20, i28-i28. LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES 1.2 TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES. Neuro-Oncology, 2018, 20, i108-i108. Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation. Strahlentherapie Und Onkologie, 2022, 198, 66-72. 114 2.0 0 Früherkennung bei Tumoren im Kindesalter. , 2003, , 127-139. High Progenitor Cell Frequency at Diagnosis Predicts High Minimal residual Disease Level in 116 1.4 0 Childhood ALL.. Blood, 2009, 114, 4705-4705. Use of IL15 Stimulated, CD3/19 Depleted Transplants From Haploidentical Donors In Pediatric Malignancies. Blood, 2010, 116, 3548-3548. 1.4 EVI-1 Mediates Apoptosis Resistance Via CD261 Induction and Enhances Leukemogenic Potential in 118 1.4 0 Human Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1356-1356. Neuroonkologie., 2014, , 277-304. Improved Immune Recovery after Transplantation of TCRαβ/CD19 Depleted Allografts from Haploidentical 120 1.4 0 Donors in Pediatric Patients. Blood, 2014, 124, 852-852. Bioluminescence in Vivo Imaging Improves the Model of Individual Patients' AML Cells Growing in Mice for Sensitive and Reliable Preclinical Treatment Trials on Various Genetic Subgroups. Blood, 2014, 124, 1.4 2323-2323. Abstract A113: iVacALL: A personalized peptide-vaccination design platform for pediatric acute 122 0 lymphoblastic leukemia patients based on patient-individual tumor-specific variants., 2016,,. Deciphering the AT/RT ligandome., 2018, 230, . Abstract 3646: (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrentPDGFRAamplification and loss ofCDKN2A/Bfollowing primary acute lymphatic leukemia and 124 0 medulloblastoma., 2019,,. Hoechst 33342 Staining Identifies the Progenitor Side Population in NOD.Cg-PrkdcscidlL2rgtmWjl/Sz 1.3 Mice Harboring Pediatric Leukemias. In Vivo, 2015, 29, 661-9. Surgical Management of Pre-Chiasmatic Intraorbital Optic Nerve Gliomas in Children after Loss of 1.5 0

MARTIN EBINGER

126 Visual Functionâ€"Resection from Bulbus to Chiasm. Children, 2022, 9, 459.

#	Article	IF	CITATIONS
127	ETMR-05. Single-cell transcriptomics of ETMR reveals developmental cellular programs and tumor-pericyte communications in the microenvironment. Neuro-Oncology, 2022, 24, i50-i50.	1.2	0